checkAd

     393  0 Kommentare Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age - Seite 3

    Contacts
    Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
    US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600

    Company Announcement no. 25 / 2023



    1 Bennett et al 2022. Lancet Infect Dis. doi: 10.1016/S1473-3099(22)00226-2


    Lesen Sie auch

    Attachment



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Bavarian Nordic Reports Data from a Phase 3 Clinical Trial of its VLP-Based Chikungunya Virus Vaccine in Adults ≥65 Years of Age - Seite 3 Study successfully met its primary endpoints Data from second pivotal Phase 3 study in people aged 12 to 64 years expected in the third quarter 2023 COPENHAGEN, Denmark, June 20, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the initial …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer